Home›Insurance›Health Insurance›Grail Galleri cancer test faces coverage uncertainty a…

Grail Galleri cancer test faces coverage uncertainty after study limits

A major study found the Galleri blood test failed to prove it could detect later-stage cancers, adding pressure to win FDA approval to clear Medicare and other insurer coverage.

Reported · Written up by our desk · Health Insurance

MarketWatch reports that Grail’s Galleri cancer screening test, which is designed to look for 50 cancers from a blood draw, has coverage uncertainty tied to whether it can secure FDA approval.

According to MarketWatch, a major study did not prove the test could detect later-stage cancers, a result that could affect how Medicare and other health insurers decide whether to pay for it.

The outcome of the FDA approval process will be a key determinant for coverage, MarketWatch adds, given that insurers typically rely on regulatory determinations for reimbursement decisions.

More like this

Sources